The NIH RADx initiative announced today that it has issued contract awards totaling $77.7 million to develop and manufacture 12 new rapid diagnostic tests for SARS-CoV-2, the virus that causes COVID-19. The home and point-of-care testing platforms target the need for high-performance, low-cost home tests and point-of-care tests that can potentially detect multiple respiratory infections.
Explore more about: Influenza
October 21, 2021
July 23, 2021
It's the rare individual who actually looks forward to getting jabbed with a needle, even if what's in the needle can protect them from a serious disease such as COVID-19. Source: National Public Radio.
September 11, 2019
Minor variants of flu strains, which are not typically targeted in vaccines, carry a bigger viral punch than previously realized, a team of scientists has found. Its research, which examined samples from the 2009 flu pandemic in Hong Kong, shows that these minor strains are transmitted along with the major strains and can replicate and elude immunizations.